{"name":"Groupe Francophone des Myelodysplasies","slug":"groupe-francophone-des-myelodysplasies","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Luspatercept Injection [Reblozyl]","genericName":"Luspatercept Injection [Reblozyl]","slug":"luspatercept-injection-reblozyl","indication":"Myelodysplastic syndromes (MDS) with ring sideroblasts","status":"phase_2"},{"name":"Azacitidine combined to Lenalidomide","genericName":"Azacitidine combined to Lenalidomide","slug":"azacitidine-combined-to-lenalidomide","indication":"Myelodysplastic syndrome (MDS), including higher-risk MDS","status":"phase_2"},{"name":"BST-236","genericName":"BST-236","slug":"bst-236","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Luspatercept Injection [Reblozyl]","genericName":"Luspatercept Injection [Reblozyl]","slug":"luspatercept-injection-reblozyl","phase":"phase_2","mechanism":"Luspatercept is a recombinant fusion protein that acts as a ligand trap for members of the TGF-β superfamily, modulating Smad2/3 signaling to enhance erythroid maturation.","indications":["Myelodysplastic syndromes (MDS) with ring sideroblasts","Beta-thalassemia"],"catalyst":""},{"name":"Azacitidine combined to Lenalidomide","genericName":"Azacitidine combined to Lenalidomide","slug":"azacitidine-combined-to-lenalidomide","phase":"phase_2","mechanism":"Azacitidine and lenalidomide work together to restore normal gene expression in myelodysplastic syndrome cells through DNA methylation inhibition and immunomodulation.","indications":["Myelodysplastic syndrome (MDS), including higher-risk MDS"],"catalyst":""},{"name":"BST-236","genericName":"BST-236","slug":"bst-236","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE91ZlhTdjJZQkp6MVExWVl0QkNsclJLYkY0Yy1QRjYzV3l0aFp3WEZmYTRMT1hYR3ptWFI4R3dSVDh0enNCQVVQbmFpUThSamsxclBmbWUzV01IWG1ka2tYUHF3Q0pHUHljaUE?oc=5","date":"2025-07-13","type":"regulatory","source":"Wiley Online Library","summary":"Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML - Sallman - 2025 - HemaSphere - Wiley Online Library","headline":"Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML - ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9KOEs4SDVobTVRNk9VMzZnUE5Pb2JMaDRLNEdWazBlRHJCcGYyYjFtUElRWmNKc1BZM0NidFkzYTQ1dS1hWEUyV2dUNUlFeG5CcWxGaEpZcmtTTUdUbEFr?oc=5","date":"2020-01-08","type":"pipeline","source":"NEJM","summary":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes - NEJM","headline":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}